|Day's range||12.70 - 13.15|
Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type
Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...
Merck Announces KEYTRUDA Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced MSI-H or dMMR Colorectal Cancer
Medical Professionals Across Merck, Pfizer and Eli Lilly Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Drugs and chemicals maker Merck KGaA on Monday became the second German blue-chip company to move its annual shareholders' meeting online after the government laid the ground for such a switch last week. "Merck will seize the opportunity created by legislators to hold the 2020 annual general meeting in a virtual format - not least to allow for a payout to shareholders of the dividend that was proposed for the 2019 business year as soon as possible," a spokesman told Reuters. Merck earlier this month proposed https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2019-q4/en/2019-Q4-Press-Release-EN.pdf a dividend of 1.30 euros ($1.44) per share.
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death
Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer
Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Merck KGaA said core earnings would see "strong" growth in 2020 when adjusted for one-offs and currency swings, but it would have to revise goals if the coronavirus outbreak does not start to ease from next month. "Should the crisis grow or trigger a global recession, the company would adapt its business forecast," it said in a statement.
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents
KEYTRUDA® Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Classical Hodgkin Lymphoma (cHL)